PTGS2 and transitional cell carcinoma: Overexpression of COX-2 has been reported in various canine cancers including transitional cell carcinoma, squamous cell carcinoma, and mammary cancer23, and the selective COX-2 inhibitor piroxicam24 has demonstrated clinical benefit against these canine cancers25–27.